Protective Effects of 5,7,3’,4’-Tetramethoxyflavone on Proliferation of Rat Chondrocytes Induced by IL-1β

Abstract:

Osteoarthritis (OA) is a degenerative joint disease that affects millions of people. Currently, there is no effective drug treatment for it. The purpose of this study is to investigate the chondroprotective effects of 5,7,3’,4’- tetramethoxyflavone in isolated cartilage chondrocytes cultured pre-treatment by IL-1β. The results showed that 5,7,3’,4’- tetramethoxyflavone could significantly down regulate the concentration of MMP-13, but up regulate the expression of TIMP-1, increase the proliferative activity of rat chondrocytes.

• Periodical: Advanced Materials Research (Volumes 998-999)
• Pages: 287-290
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.998-999.287
• Online since: July 2014
• Authors: Zhao Wen Liu, Hai Qing Liu, Lin Fu Li, Liang Yu Jiao, Long Huo Wu*
• Keywords: 5,7,3’,4’- Tetramethoxyflavone, MMP-13, Osteoarthritis, TIMP-1

References

[1] Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012; 51: 249-257.

DOI: 10.1016/j.bone.2012.02.012

[2] Hou CH, Tang CH, Hsu CJ, Hou SM, Liu JF. CCN4 induces IL-6 production through avb5 receptor, PI3K, Akt, and NF-κB singling pathway in human synovial fibroblasts. Arthritis Res Ther 2013; 15: R19.

DOI: 10.1186/ar4151

[3] Zamli Z, Sharif M. Chondrocyte apoptosis: a cause or consequence of osteoarthritis? Int J Rheum Dis 2011; 14: 159-166.

DOI: 10.1111/j.1756-185x.2011.01618.x

[4] Wei L, Sun XJ, Wang Z, Chen Q. CD95-induced osteoarthritic chondrocyte apoptosis and necrosis: dependency on p.38 mitogen-activated protein kinase. Arthritis Res Ther 2006; 8: R37.

[5] Kuhn K, D'Lima DD, Hashimoto S, Lotz M. Cell death in cartilage. Osteoarthritis Cartilage 2004; 12: 1-16.

DOI: 10.1016/j.joca.2003.09.015

[6] Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–1544.

DOI: 10.1002/art.1780390914

[7] Wu L, Li P, Wang X, Zhuang Z, Farzaneh F, Xu R. Evaluation of anti-inflammatory and anti-nociceptive activities of Murraya Exotica. Pharmaceutical Biology, vol. 48, no. 12, pp.1344-1353, (2010).

DOI: 10.3109/13880201003793723

[8] Burrage PS, Mix KS, Brinckerhoff CE. Matrix metal-loproteinases: role in arthritis. Front Biosci 2006; 11: 529-543.

[9] Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282: 27781-27791.

DOI: 10.1074/jbc.m703286200

[10] Takaishi H, Kimura T, Dalah S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Phramac Biotechnol. 2008; 9: 47-54.

DOI: 10.2174/138920108783497659

[11] Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-3727.

DOI: 10.1242/jcs.00063

[12] Upadhyay A, Sharma G, Kivivuori S, et al. Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes. Cytokine 2009; 46: 332-338.

DOI: 10.1016/j.cyto.2009.03.001